Lamotrigine rash risk and titration.

• A. Rash risk is minimized with slow titration; monitor for rash especially within the first weeks.
• B. Rash risk is increased with slow titration; rash occurs within months.
• C. Lamotrigine has no risk of rash.
• D. Rash is common only in elderly patients.

Answer: (A)

Starting lamotrigine with a slow, gradual dose increase lowers the chance of developing a rash because the body isn’t exposed to high drug levels all at once. The most important period for rash risk is the early weeks of therapy, when rash is most likely to appear. Because of this, the strategy is to start very low and titrate slowly while closely watching for signs of a skin reaction. If a rash develops, lamotrigine should be stopped promptly to prevent progression to more serious conditions, since severe cutaneous reactions can occur early in treatment.

This fits the statement that rash risk is minimized with slow titration and that monitoring for rash is especially important in the first weeks. The other ideas aren’t correct: rash risk isn’t increased by slow titration, rash can occur months after starting, lamotrigine does carry rash risk, and rash isn’t confined to the elderly.